<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37789144</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial.</ArticleTitle><Pagination><StartPage>2902</StartPage><EndPage>2908</EndPage><MedlinePgn>2902-2908</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-023-02576-1</ELocationID><Abstract><AbstractText>Previous studies showed a low-grade enterovirus infection in the pancreatic islets of patients with newly diagnosed type 1 diabetes (T1D). In the Diabetes Virus Detection (DiViD) Intervention, a phase 2, placebo-controlled, randomized, parallel group, double-blind trial, 96 children and adolescents (aged 6-15 years) with new-onset T1D received antiviral treatment with pleconaril and ribavirin (n = 47) or placebo (n = 49) for 6 months, with the aim of preserving β cell function. The primary endpoint was the mean stimulated C-peptide area under the curve (AUC) 12 months after the initiation of treatment (less than 3 weeks after diagnosis) using a mixed linear model. The model used longitudinal log-transformed serum C-peptide AUCs at baseline, at 3 months, 6 months and 1 year. The primary endpoint was met with the serum C-peptide AUC being higher in the pleconaril and ribavirin treatment group compared to the placebo group at 12 months (average marginal effect = 0.057 in the linear mixed model; 95% confidence interval = 0.004-0.11, P = 0.037). The treatment was well tolerated. The results show that antiviral treatment may preserve residual insulin production in children and adolescent with new-onset T1D. This provides a rationale for further evaluating antiviral strategies in the prevention and treatment of T1D. European Union Drug Regulating Authorities Clinical Trials identifier: 2015-003350-41 .</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Krogvold</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mynarek</LastName><ForeName>Ida Maria</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0009-0004-1420-3359</Identifier><AffiliationInfo><Affiliation>Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponzi</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Trial Unit, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mørk</LastName><ForeName>Freja Barrett</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Steno Diabetes Center Copenhagen, Herlev University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hessel</LastName><ForeName>Trine Witzner</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Steno Diabetes Center Copenhagen, Herlev University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roald</LastName><ForeName>Trine</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindblom</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Apodemus AB, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westman</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Apodemus AB, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Institute for Health and Care Research Cambridge Biomedical Research Centre, Core Biochemistry Assay Laboratory, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyöty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludvigsson</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1695-5234</Identifier><AffiliationInfo><Affiliation>Linköping University, Linköping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanssen</LastName><ForeName>Kristian F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannesen</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Steno Diabetes Center Copenhagen, Herlev University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl-Jørgensen</LastName><ForeName>Knut</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6952-9899</Identifier><AffiliationInfo><Affiliation>Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway. knut.dahl-jorgensen@medisin.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Oslo, Oslo, Norway. knut.dahl-jorgensen@medisin.uio.no.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002096">C-Peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002096" MajorTopicYN="N">C-Peptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>H.H. is a shareholder and member of the board of Vactech Ltd, which develops vaccines against picornaviruses. N.L. and J.W. are employees of Apodemus/Curovir AB, which own the rights to the commercialization of the results of this trial. Curovir AB is developing antiviral drugs for enterovirus-induced diseases. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37789144</ArticleId><ArticleId IdType="pmc">PMC10667091</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02576-1</ArticleId><ArticleId IdType="pii">10.1038/s41591-023-02576-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–2054. doi: 10.2337/dc14-1140.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-1140</ArticleId><ArticleId IdType="pmc">PMC5865481</ArticleId><ArticleId IdType="pubmed">24935775</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawshani A, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392:477–486. doi: 10.1016/S0140-6736(18)31506-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31506-X</ArticleId><ArticleId IdType="pmc">PMC6828554</ArticleId><ArticleId IdType="pubmed">30129464</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes—considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015;38:979–988. doi: 10.2337/dc15-0144.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-0144</ArticleId><ArticleId IdType="pmc">PMC4439528</ArticleId><ArticleId IdType="pubmed">25998290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 2010;6:279–289. doi: 10.1038/nrendo.2010.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2010.27</ArticleId><ArticleId IdType="pubmed">20351698</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun HS, Yoon JW. The role of viruses in type I diabetes: two distinct cellular and molecular pathogenic mechanisms of virus-induced diabetes in animals. Diabetologia. 2001;44:271–285. doi: 10.1007/s001250051614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001250051614</ArticleId><ArticleId IdType="pubmed">11317656</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K, et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat. Med. 2019;25:1865–1872. doi: 10.1038/s41591-019-0667-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pmc">PMC6898786</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId></ArticleIdList></Reference><Reference><Citation>de Crom SC, Rossen JW, van Furth AM, Obihara CC. Enterovirus and parechovirus infection in children: a brief overview. Eur. J. Pediatr. 2016;175:1023–1029. doi: 10.1007/s00431-016-2725-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-016-2725-7</ArticleId><ArticleId IdType="pmc">PMC4930465</ArticleId><ArticleId IdType="pubmed">27156106</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel RA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38:1964–1974. doi: 10.2337/dc15-1419.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-1419</ArticleId><ArticleId IdType="pmc">PMC5321245</ArticleId><ArticleId IdType="pubmed">26404926</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs SR, et al. Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol. 2023;11:578–592. doi: 10.1016/S2213-8587(23)00122-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(23)00122-5</ArticleId><ArticleId IdType="pubmed">37390839</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner CL, et al. The virome in early life and childhood and development of islet autoimmunity and type 1 diabetes: a systematic review and meta-analysis of observational studies. Rev. Med. Virol. 2021;31:1–14. doi: 10.1002/rmv.2209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2209</ArticleId><ArticleId IdType="pmc">PMC8518965</ArticleId><ArticleId IdType="pubmed">33378601</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia. 2013;56:185–193. doi: 10.1007/s00125-012-2745-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2745-4</ArticleId><ArticleId IdType="pubmed">23064357</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia. 2014;57:841–843. doi: 10.1007/s00125-013-3155-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-013-3155-y</ArticleId><ArticleId IdType="pubmed">24429579</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, et al. Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. Diabetologia. 2022;65:2108–2120. doi: 10.1007/s00125-022-05779-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05779-2</ArticleId><ArticleId IdType="pmc">PMC9630231</ArticleId><ArticleId IdType="pubmed">35953727</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, et al. Detection of a low-grade enteroviral infection in the islets of Langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes. 2015;64:1682–1687. doi: 10.2337/db14-1370.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-1370</ArticleId><ArticleId IdType="pubmed">25422108</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, et al. Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia. 2021;64:2491–2501. doi: 10.1007/s00125-021-05525-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-021-05525-0</ArticleId><ArticleId IdType="pmc">PMC8494699</ArticleId><ArticleId IdType="pubmed">34390364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifie E, et al. Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia. 2018;61:2344–2355. doi: 10.1007/s00125-018-4704-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4704-1</ArticleId><ArticleId IdType="pmc">PMC6182664</ArticleId><ArticleId IdType="pubmed">30074059</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne JL, et al. Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia. 2019;62:744–753. doi: 10.1007/s00125-019-4811-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-019-4811-7</ArticleId><ArticleId IdType="pmc">PMC6450860</ArticleId><ArticleId IdType="pubmed">30675626</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg A-K, Olsson A, Korsgren O, Frisk G. Antiviral treatment of Coxsackie B virus infection in human pancreatic islets. Antiviral Res. 2007;74:65–71. doi: 10.1016/j.antiviral.2006.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2006.12.001</ArticleId><ArticleId IdType="pubmed">17239967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antivir. Ther. 2002;7:53–65. doi: 10.1177/135965350200700107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135965350200700107</ArticleId><ArticleId IdType="pubmed">12008788</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkimaa A, et al. Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs. J. Clin. Virol. 2020;128:104334. doi: 10.1016/j.jcv.2020.104334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104334</ArticleId><ArticleId IdType="pubmed">32450550</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug MJ, et al. A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J. Pediatric. Infect. Dis. Soc. 2016;5:53–62. doi: 10.1093/jpids/piv015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piv015</ArticleId><ArticleId IdType="pmc">PMC4765488</ArticleId><ArticleId IdType="pubmed">26407253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine AB, Honkimaa A, Hyöty H. A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Diabet. Med. 2020;37:1849–1853. doi: 10.1111/dme.14175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.14175</ArticleId><ArticleId IdType="pubmed">31705692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsi JJ, et al. Broad-spectrum antiviral activity of 2-beta-d-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. 1983;24:353–361. doi: 10.1128/AAC.24.3.353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.24.3.353</ArticleId><ArticleId IdType="pmc">PMC185325</ArticleId><ArticleId IdType="pubmed">6615611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupke P, et al. Immunomodulation of natural killer cell function by ribavirin involves TYK-2 activation and subsequent increased IFN-γ secretion in the context of in vitro hepatitis E virus infection. Cells. 2023;12:453. doi: 10.3390/cells12030453.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12030453</ArticleId><ArticleId IdType="pmc">PMC9913562</ArticleId><ArticleId IdType="pubmed">36766795</ArticleId></ArticleIdList></Reference><Reference><Citation>Geravandi S, Liu H, Maedler K. Enteroviruses and T1D: is it the virus, the genes or both which cause T1D. Microorganisms. 2020;8:1017. doi: 10.3390/microorganisms8071017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8071017</ArticleId><ArticleId IdType="pmc">PMC7409303</ArticleId><ArticleId IdType="pubmed">32650582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM. Persistent enterovirus infection: little deletions, long infections. Vaccines. 2022;10:770. doi: 10.3390/vaccines10050770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050770</ArticleId><ArticleId IdType="pmc">PMC9143164</ArticleId><ArticleId IdType="pubmed">35632526</ArticleId></ArticleIdList></Reference><Reference><Citation>Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus—why the β cells? Nat. Rev. Endocrinol. 2016;12:263–273. doi: 10.1038/nrendo.2016.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2016.30</ArticleId><ArticleId IdType="pmc">PMC5348720</ArticleId><ArticleId IdType="pubmed">27020257</ArticleId></ArticleIdList></Reference><Reference><Citation>Marroqui L, et al. Differential cell autonomous responses determine the outcome of coxsackievirus infections in murine pancreatic α and β cells. eLife. 2015;4:e06990. doi: 10.7554/eLife.06990.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.06990</ArticleId><ArticleId IdType="pmc">PMC4480275</ArticleId><ArticleId IdType="pubmed">26061776</ArticleId></ArticleIdList></Reference><Reference><Citation>Eizirik DL, Miani M, Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia. 2013;56:234–241. doi: 10.1007/s00125-012-2762-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2762-3</ArticleId><ArticleId IdType="pubmed">23132339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouin A, et al. Enterovirus persistence in cardiac cells of patients with idiopathic dilated cardiomyopathy is linked to 5′ terminal genomic RNA-deleted viral populations with viral-encoded proteinase activities. Circulation. 2019;139:2326–2338. doi: 10.1161/CIRCULATIONAHA.118.035966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035966</ArticleId><ArticleId IdType="pmc">PMC6517084</ArticleId><ArticleId IdType="pubmed">30755025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahrs CR, et al. Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort. BMJ. 2019;364:l231. doi: 10.1136/bmj.l231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l231</ArticleId><ArticleId IdType="pmc">PMC6372922</ArticleId><ArticleId IdType="pubmed">30760441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindfors K, et al. Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study. Gut. 2020;69:1416–1422. doi: 10.1136/gutjnl-2019-319809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319809</ArticleId><ArticleId IdType="pmc">PMC7234892</ArticleId><ArticleId IdType="pubmed">31744911</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M, et al. Enterovirus infections are associated with the development of celiac disease in a birth cohort study. Front. Immunol. 2021;11:604529. doi: 10.3389/fimmu.2020.604529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.604529</ArticleId><ArticleId IdType="pmc">PMC7884453</ArticleId><ArticleId IdType="pubmed">33603739</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson WH, Steinman L. Epstein–Barr virus and multiple sclerosis. Science. 2022;375:264–265. doi: 10.1126/science.abm7930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm7930</ArticleId><ArticleId IdType="pubmed">35025606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammerstad SS, et al. Detection of enterovirus in the thyroid tissue of patients with Graves’ disease. J. Med. Virol. 2013;85:512–518. doi: 10.1002/jmv.23476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23476</ArticleId><ArticleId IdType="pubmed">23280563</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, et al. Function of isolated pancreatic islets from patients at onset of type 1 diabetes: insulin secretion can be restored after some days in a non-diabetogenic environment in vitro: results from the DiViD study. Diabetes. 2015;64:2506–2512. doi: 10.2337/db14-1911.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-1911</ArticleId><ArticleId IdType="pubmed">25677915</ArticleId></ArticleIdList></Reference><Reference><Citation>In’t Veld P. Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin. Immunopathol. 2014;36:569–579. doi: 10.1007/s00281-014-0438-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-014-0438-4</ArticleId><ArticleId IdType="pmc">PMC4186970</ArticleId><ArticleId IdType="pubmed">25005747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondelli MU. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? Hepatology. 2014;60:1126–1129. doi: 10.1002/hep.27186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27186</ArticleId><ArticleId IdType="pubmed">24753082</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen LM, et al. Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Technol. Ther. 2020;22:948–953. doi: 10.1089/dia.2020.0305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2020.0305</ArticleId><ArticleId IdType="pmc">PMC7757538</ArticleId><ArticleId IdType="pubmed">32833543</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza GP, et al. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA. 2023;329:990–999. doi: 10.1001/jama.2023.2064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.2064</ArticleId><ArticleId IdType="pmc">PMC9960020</ArticleId><ArticleId IdType="pubmed">36826844</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyam A, et al. Clinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications. Diabetes Care. 2021;44:390–398. doi: 10.2337/dc20-0567.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0567</ArticleId><ArticleId IdType="pubmed">33303639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenheimer HC, Jr, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26:437–477. doi: 10.1002/hep.510260231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.510260231</ArticleId><ArticleId IdType="pubmed">9252161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunger DB, et al. INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes. Trials. 2022;23:414. doi: 10.1186/s13063-022-06259-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06259-z</ArticleId><ArticleId IdType="pmc">PMC9116021</ArticleId><ArticleId IdType="pubmed">35585600</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenbaum CJ, et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008;31:1966–1971. doi: 10.2337/dc07-2451.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc07-2451</ArticleId><ArticleId IdType="pmc">PMC2551636</ArticleId><ArticleId IdType="pubmed">18628574</ArticleId></ArticleIdList></Reference><Reference><Citation>Brede C, Hop B, Jørgensen K, Skadberg Ø. Measurement of glycated albumin in serum and plasma by LC–MS/MS. Scand. J. Clin. Lab. Invest. 2016;76:195–201. doi: 10.3109/00365513.2015.1129671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365513.2015.1129671</ArticleId><ArticleId IdType="pubmed">26898156</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkanen H, et al. Human enterovirus 71 strains in the background population and in hospital patients in Finland. J. Clin. Virol. 2013;56:348–353. doi: 10.1016/j.jcv.2012.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2012.11.018</ArticleId><ArticleId IdType="pubmed">23261080</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer JP, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes. 2004;53:250–264. doi: 10.2337/diabetes.53.1.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.53.1.250</ArticleId><ArticleId IdType="pubmed">14693724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson J, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 2008;359:1909–1920. doi: 10.1056/NEJMoa0804328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0804328</ArticleId><ArticleId IdType="pubmed">18843118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundy BN, Krischer JP. A model-based approach to sample size estimation in recent onset type 1 diabetes. Diabetes Metab. Res. Rev. 2016;32:827–834. doi: 10.1002/dmrr.2800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.2800</ArticleId><ArticleId IdType="pmc">PMC5117187</ArticleId><ArticleId IdType="pubmed">26991448</ArticleId></ArticleIdList></Reference><Reference><Citation>Searle SR, Speed FM, Milliken GA. Population marginal means in the linear model: an alternative to least squares means. Am. Stat. 1980;34:216–221.</Citation></Reference><Reference><Citation>Coffman CJ, Edelman D, Woolson RF. To condition or not condition? Analysing ‘change’ in longitudinal randomised controlled trials. BMJ Open. 2016;6:e013096. doi: 10.1136/bmjopen-2016-013096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-013096</ArticleId><ArticleId IdType="pmc">PMC5223669</ArticleId><ArticleId IdType="pubmed">28039292</ArticleId></ArticleIdList></Reference><Reference><Citation>Twisk, J. W. R. Analysis of Data from Randomized Controlled Trials: a Practical Guide Chap. 3 (Springer, 2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>